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Abstract 
Background: With the advent of newer antipsychotic drugs, side effects such as sexual dysfunction have 
been a major contributor toward treatment compliance. There are only a few studies that have compared 
different atypical antipsychotic agents regarding sexual dysfunction. We have not come across any data 
in this area on Indian population. Aims: To determine and compare the frequency of sexual dysfunction 
associated with risperidone, olanzapine, and quetiapine, among patients with clinically stable 
schizophrenia. Settings and Design: It is a cross-sectional hospital-based study. The subjects were 
recruited for the study by the purposive sampling technique. Materials and Methods: The total sample 
size was 102, consisting of 25 each in the quetiapine and risperidone groups, 22 in the olanzapine group, 
and 30 healthy volunteers. A Brief Psychiatric Rating Scale and Sexual Functioning Questionnaire (SFQ) 
were administered. The Kruskal Wallis test was used to compare the variables in the demographic data 
and the mean chlorpromazine equivalent doses of the study groups. To analyze the sexual dysfunction, 
the mean scores on all the domains of sexual functioning in SFQ were compared across the study groups 
using the Chi square test, for proportions. Results and Conclusion: Twenty-three percent of the healthy 
volunteers had some impairment in one or more domains of sexual functioning. For the medication 
groups this was 96, 88, and 90%, respectively for risperidone, quetiapine, and olanzapine. However, there 
was statistically no significant difference across the study groups although it was relatively less with 
quetiapine. 
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Background: With the advent of newer antipsychotic drugs, side effects such as sexual dysfunction have been a major 
contributor toward treatment compliance. There are only a few studies that have compared different atypical 
antipsychotic agents regarding sexual dysfunction. We have not come across any data in this area on Indian 
population. Aims: To determine and compare the frequency of sexual dysfunction associated with risperidone, 
olanzapine, and quetiapine, among patients with clinically stable schizophrenia. Settings and Design: It is a cross-
sectional hospital-based study. The subjects were recruited for the study by the purposive sampling technique. 
Materials and Methods: The total sample size was 102, consisting of 25 each in the quetiapine and risperidone 
groups, 22 in the olanzapine group, and 30 healthy volunteers. A Brief Psychiatric Rating Scale and Sexual 
Functioning Questionnaire (SFQ) were administered. The Kruskal Wallis test was used to compare the variables in the 
demographic data and the mean chlorpromazine equivalent doses of the study groups. To analyze the sexual 
dysfunction, the mean scores on all the domains of sexual functioning in SFQ were compared across the study groups 
using the Chi square test, for proportions. Results and Conclusion: Twenty-three percent of the healthy volunteers 
had some impairment in one or more domains of sexual functioning. For the medication groups this was 96, 88, and 
90%, respectively for risperidone, quetiapine, and olanzapine. However, there was statistically no significant 











Sexual function is the physiological capacity to experience desire, arousal, and orgasm. Sexual dysfunction can result 
from a wide variety of psychological and physical causes. Among drugs, antihypertensives, diuretics, antihistamines, 
antidepressants, benzodiazepines, and antipsychotics are the common agents associated with sexual dysfunction. [1] 
Schizophrenic patients can develop sexual dysfunction that may not be related to drugs. Studies have shown that a 
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majority of untreated schizophrenic patients have a reduced desire for sex, more in females as compared to males, 
although arousal and ejaculatory functions remain relatively intact. The schizophrenic men often limit their sexual 
activity to masturbation, as the negative symptoms limit their ability to maintain relationships. [2] However, while on 
treatment, they may experience erectile dysfunction and orgasmic difficulties as adverse effects of the medicines, that 
is, antipsychotics, unless they have no primary organic pathology or comorbid medical conditions contributing to the 
sexual dysfunction. [3],[4] Thus, the major impact on sexual functioning in schizophrenic patients is by antipsychotics. 
There are sufficient studies that have looked into sexual dysfunction due to typical antipsychotics as well as studies 
that have compared typical and atypical antipsychotic agents. [5],[6],[7],[8],[9] However, there are only a few studies 
that have compared different atypical antipsychotic agents for sexual dysfunction. [10],[11] The authors have not come 
across such studies among the Indian population. 
 
 Materials and Methods 
 
 
The study sample was taken from the Psychiatry Outpatient Department and it consisted of 72 patients with clinically 
stable schizophrenia meeting the ICD-10 criteria; as well as 30 healthy volunteers from among the staff of the hospital 
and caregivers of patients who were willing to participate in the study. This is a cross-sectional, hospital-based study. 
After obtaining the local ethical committee clearance, the subjects were recruited for the study by the purposive 
sampling technique during August 2005-April 2006. The sample (N = 102) was divided into four groups [Table 1]. 
Group one (G 1 ) consisted of 25 patients on risperidone, group two (G 2 ) had 25 patients on quetiapine, group three 
(G 3 ) was made up of 22 patients on olanzapine, and group four (G 4 ) had 30 healthy volunteers. These drugs were 
not administered for the purpose of the study. The patients, who were maintaining remission on one of these drugs, 
taken in the oral form tablets, were enrolled into the study during their regular follow up, after their written consent. 
Study-related assessments were done on the same day of selecting the patients for the study. 
 
The sample consisted of male patients between 18-50 years of age, sexually active (not abstinent) and on regular 
treatment with a stable dose of risperidone, quetiapine, or olanzapine for at least six weeks after achieving clinical 
stability. Female patients were not included in the study as the types of questions in the SFQ were not suitable for the 
conservative female population of this locality or for their cooperation to answer them. Remission was defined by a 
score of less than 4 on all items of BPRS. [12] Patients having other comorbid medical and psychiatric illnesses as 
well as primary sexual dysfunction were not included. Furthermore, those on more than one antipsychotic drug or 
other drugs affecting sexual function, like benzodiazepines, antidepressants, and antihypertensives were also not 
included. The only allowed medication along with the above-mentioned antipsychotics was trihexyphenidyl, given to 
control extrapyramidal side effects.  
 
The sociodemographic and clinical information sheet, BPRS, and SFQ [6] were the tools used for assessing the 
patients. The SFQ was the modified version of a questionnaire used by Burke et al. [13] For those who did not know 
English, a vernacular translation was administered by the author. The SFQ asked detailed questions about the physical 
aspects of sexual functioning including libido, physical arousal, masturbation, orgasm (including painful orgasm), and 
ejaculation. It had been further modified so that it had subscales for the different areas of sexual functioning. It was not
necessary for the subject to have a partner in order to complete it. The scale, though not tested adequately for validity, 
had good reliability: Cronbach's α = 0.90; Guttman's split-half reliability = 0.86. For the purpose of statistical analysis, 
an arbitrary cut off point of one standard deviation above the mean was taken as the threshold above which sexual 
dysfunction was said to be present. Taking that into consideration, the subscales of the questionnaire served as 
continuous variables, which were studied across the study groups.  
 
Patients with clinically stable schizophrenia, as per ICD-10 criteria, attending the Department of Psychiatry were 
interviewed after taking informed consent. After collecting the required sociodemographic and clinical data from the 
patients, they were rated on BPRS, to rule out any active psychopathology. Subsequently, they were rated on the SFQ 
to determine the dysfunction in the phases of desire, arousal, and orgasm. Healthy volunteers who were medically fit 
and not on any medication were asked to fill a sociodemographic data sheet as well as sexual functioning 





The statistical analysis of data was performed using SPSS for Windows (version 12.0) and Microsoft Excel.  
 
Descriptive statistics were applied to obtain the means and frequencies of sociodemographic and clinical data of the 
sample. Subsequently, the Kolmogorov-Smirnov test was used to check for normality of distribution of data on the 
sexual functioning questionnaire (SFQ). It was found that most of the data was not normally distributed. Thus non-
parametric tests were used for comparative statistics. The Kruskal Wallis test was used to compare the continuous 
variables in demographic data as well as mean chlorpromazine equivalent doses of the three study groups.  
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To analyze the sexual dysfunction, the mean scores of the sexual functioning questionnaire on the domains of desire, 
arousal/erection, orgasm/ejaculation, and overall sexual impairment was obtained. The SFQ is designed such that the 
higher the score, more severe is the sexual dysfunction. An arbitrary cut off point of 1 SD above the mean score of 
healthy volunteers (G 4 ) was taken as the threshold above which sexual dysfunction was said to be present. The mean 
scores on all the domains were compared across the study groups using the Chi square test, as proportions and level of 





The groups were evenly matched with respect to key clinical variables, such as, age, duration of illness, duration of 
clinical stability, and treatment duration as shown in [Table 2] and [Table 3]. A majority of them were educated above 
higher secondary school. Illiterates constituted 7.8%. The occupation of most of the study subjects was agricultural 
farming (26.5%) and the family income of most of them (28.4%) was in the range of Rs 2000-3000 per month. Two-
thirds of the subjects were from extended families and the same proportion was married. A majority of them had 
received the diagnosis of paranoid schizophrenia (62.5%). Out of the 72 patients, only six were clinically stable 
beyond one year (four in the risperidone group and two in the quetiapine group). The rest of them were stable for less 
than one year, but more than six months at the time of data collection. Though clinically insignificant, the risperidone 
group had comparatively a lesser duration of active illness and a greater duration of clinical stability. Further, the 
duration of medication use at the time of assessment was also less, although not clinically significant, for the 
risperidone group. 
 
It was important to look for the normality of distribution of data on the SFQ, before applying for the statistical tests. 
This was analyzed by applying the Kolmogorov-Smirnov test. It was found that a majority of the variables were not 
normally distributed. The scores for desire in the risperidone and quetiapine groups and the overall sexual dysfunction 
scores for the risperidone, olanzapine, and healthy volunteer groups followed a normal distribution, but not the 
remaining majority of items. This is shown in [Table 4]. Thus nonparametric tests were applied to analyze the sexual 
dysfunction. As only clinically stable patients were selected, their scores on BPRS were not compared statistically.  
 
The mean (SD) daily doses of the three drugs were found to be 5.2 (1.65) mg, 468.0 (141.33) mg, and 13.86 (4.06) mg 
for risperidone, quetiapine, and olanzapine, respectively. Their mean (SD) chlorpromazine equivalent doses were 
260.00 (82.60) mg for risperidone, 936.00 (282.00) mg for quetiapine, and 351.13 (101.61) mg for olanzapine. The 
chlorpromazine equivalent doses of the three drugs were compared using the Kruskal Wallis test, as the data here was 
also not normally distributed. This data is shared in [Table 5]. The quetiapine dose was significantly higher ( P = 
0.000) compared to the other drugs. These finding show that a higher chlorpromazine equivalent dose of quetiapine 
may be required compared to risperidone and olanzapine, for achieving and maintaining clinical stability in 
schizophrenia. 
 
Sexual side effects - Frequency and severity 
 
Sexual side effects across the three drug groups were compared on SFQ for frequency as well as severity of all the 
domains, that is, desire, arousal/erection, orgasm/ejaculation, and overall sexual impairment. The Sexual Functioning 
Questionnaire is a sensitive tool, with 38 items that assess sexual functioning. About 23% of the healthy volunteers 
had their score above 1 SD of the mean, thus having some impairment in one or the other domain of sexual 
functioning. For the medication groups this was 96, 88, and 90%, for risperidone, quetiapine and olanzapine, 
respectively. Desire was most commonly impaired in the risperidone group (80%) as compared to 72% in the 
quetiapine group, and 78% in the olanzapine group. Erectile dysfunction was most common in the olanzapine group 
(50%). It was 40% in the risperidone group and 36% in the quetiapine group. Orgasmic dysfunction was equally 
common to both the risperidone and quetiapine (32%) groups and 27% in the olanzapine group. This is shown in 
[Table 6]. 
 
Comparison of sexual dysfunction across study groups 
 
The mean scores from SFQ on all domains of sexual functioning of the three medication groups were compared by the 
c0 hi square test for proportions with the healthy volunteer group. Although the mean scores of the quetiapine group 
for overall sexual side effects, desire, and arousal/erectile impairment were less than the other two medication groups, 
there was no significant difference across the three groups in any of the domains of sexual dysfunction. The details of 





Overall sexual impairment 
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The diagnosis of sexual dysfunction is not absolute. Persons with adequate sexual functioning show enormous 
variability in frequency of sexual activity and desire; and normal sexuality may include an occasional dysfunctional 
moment. The literature addressing the western population report that about 10-15% of the normal population suffers 
from sexual dysfunction. [14] The SFQ recognized sexual dysfunction in 17% of the normal western population. [6] In 
the current study using the same SFQ, sexual dysfunction was recognized in 23% of the healthy volunteers. This is 
slightly higher than the western figures. However, the total mean score on SFQ of the healthy volunteers, in the 
original study, was 12.1 ± 6.9 and in the current study it is 9.86 ± 3.84. In other words, the severity of sexual 
dysfunction, (quantified by mean score) which has a greater impact, appears to be more or less the same. 
 
In this study risperidone was associated with the most frequent overall sexual impairment (96%) compared to 
olanzapine (90%) and quetiapine (88%), although it was not statistically significant. Melkersson has also reported an 
overall sexual dysfunction of 89% due to risperidone. [15] Up to 93% of risperidone-treated patients reported an 
overall impairment of sexual functioning in yet another study. [16] Even in the case of olanzapine and quetiapine, a 
frequency of overall sexual impairment, comparable to our study, was observed in other studies. [10],[16] Kelly and 
Conley had compared fluphenazine, risperidone, and quetiapine and reported a much higher degree of sexual 
dysfunction with quetiapine compared to all other previous studies. It was a randomized, double blind 12-week study, 
reporting overall sexual impairment as high as 50% with quetiapine as compared to 42% with risperidone and 78% 
with fluphenazine. The study also looked into the prolactin levels due to study drugs. An interesting aspect in this 
study was that quetiapine had overtaken risperidone in the frequency of sexual dysfunction, although risperidone 
caused the highest levels of prolactin elevation and quetiapine caused none. This indicated that prolactin elevation was 
not the only mechanism behind drug-induced sexual dysfunction, and that quetiapine could also cause a substantial 
degree of sexual dysfunction, although it was not associated with the elevation of prolactin levels. [16] Nonetheless, 
the present study supports this finding especially with respect to the higher frequency of quetiapine-associated sexual 
dysfunction.  
 
Another recent study compared risperidone, olanzapine, and quetiapine for sexual dysfunction using a different 
questionnaire called Arizona Sexual Experience Scale (ASEX). It was also a cross-sectional study like the present one 
with a sample size of 238 (quetiapine-57, olanzapine-94, risperidone-87). The mean scores on ASEX were relatively 
low in the quetiapine group compared to the other two drugs, as in our study. The patients in all the treatment groups, 
nonetheless, experienced a moderately high degree of sexual dysfunction. However, the quetiapine group experienced 
a slightly lesser degree of sexual dysfunction, although it differed significantly only with the olanzapine group. [10] 
Our study supports the findings of this study too, with respect to the sexual side-effect frequency of quetiapine that is 
comparable to risperidone and olanzapine. This is contrary to the earlier evidence that assigned a better safety profile 




Impaired desire is the most frequently reported sexual dysfunction among all the medication groups in the present 
study. An assessment of changes in libido associated with psychotropic medications can be difficult, because 
psychiatric illnesses can significantly affect sexual interest. In symptomatic cases of schizophrenia with prominent 
negative symptoms, the frequency of sexual fantasy is much reduced and their sexual activity is reduced to 
masturbation. [17] The effects of antipsychotics on libido are not as well characterized as other forms of sexual 
dysfunction, in part because of the difficulty in measuring changes in libido. Nevertheless, several factors influence 
desire. Failure of erection may itself adversely affect a patient's desire. A patient's socioeconomic status and quality of 
life also influence his libido. Libido was the most frequently reported sexual dysfunction with both haloperidol (58%) 
and clozapine (50%), in one of the studies. [18] Of late, another study reported that impaired desire (44%) was the 
most common sexual dysfunction due to risperidone. [15] One more study reported that impaired libido is commonly 
seen even with quetiapine. [19] These finding are supported by the present study, which reports an impaired libido of 
80% with risperidone, 72% with quetiapine, and 78% with olanzapine. However, considering the facts discussed 
earlier in this section, it would be difficult to conclude that the drugs are entirely responsible for the higher rate of 
impaired libido reported in this study. We cannot exclude the role of illness sharing to some extent the impairment of 
libido experienced by the patients. An elevated prolactin level is an important biological marker of impaired libido due 
to antipsychotics. This index can be of some help to know to what extent the drug and the illness are attributable for 




Erectile problem was the second most frequent sexual side effect in the current study. Among the three drugs, 
olanzapine was most commonly associated with erectile dysfunction (50%) as compared to risperidone (40%) and 
quetiapine (36%). However, it was not statistically significant. While many studies reported desire to be the most 
common sexual side effect due to antipsychotics, a good number of studies inferred that erectile failure was also an 
equally common sexual side effect. However, it was easier to measure and quantify erectile dysfunction compared to 
libido, due to the availability of procedures like measuring nocturnal tumescence and penile plethysmography. 
Furthermore, it was also easier for the patient to appreciate and report his erectile problems compared to diminished 
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libido. One study reported erectile difficulties associated with antipsychotic drugs in 38% schizophrenic patients, [19] 
followed by 47% in another study, [26] and 52% in yet another. [8] However, these studies included typical 
antipsychotics too. In one of the studies on Indian population, the erectile dysfunction was 53% with typical 
antipsychotics and 31% with atypical antipsychotics and it differed significantly ( P = 0.025). However, the tool used 
for assessment was the UKU side effect rating scale. No comprehensive questionnaire was used. [9] The frequency of 




In a majority of the published studies, orgasmic and ejaculatory problems were less commonly reported than the desire 
and erection problems associated with antipsychotics. This is especially true in the case of atypical antipsychotics. A 
common problem in assessing orgasmic and ejaculatory problems is the co-occurrence of erectile dysfunction. In such 
cases the patient cannot satisfactorily recognize their ejaculatory and orgasmic function. As he cannot achieve 
complete erection, he may not ejaculate and experience orgasmic joy even though his orgasmic capacity is intact. This 
limitation could not be answered in our study too. Orgasmic and ejaculatory problems were least affected among the 
patients in the present study. Thirty-two percent of the patients on risperidone and quetiapine and 27% of those on 
olanzapine had orgasmic/ejaculatory problems. In a study by Wirshing and co-workers, orgasmic and ejaculatory 
difficulties were found in 86% of the patients on risperidone as compared to 20% on clozapine. Nevertheless, the 
sample size was too small (n = 14 for risperidone and n = 5 for clozapine) and a Type II error was clearly evident. [20] 
One of the recent studies reported that patients on quetiapine had better orgasmic quality and ability compared to 
risperidone and fluphenazine. [16] However, in the present study the orgasmic capacity was equally impaired in both 
the risperidone and quetiapine groups. In the former study, the patients received drugs for only 12 weeks, whereas, in 
the current study the duration of treatment was beyond six months, in fact more than a year in many of them. This 
could explain the difference in impairment of orgasm between the two studies.  
 
This is a single contact hospital-based study done to test the hypothesis formulated, based on the available literature, 
and aimed at assessing the frequency of sexual dysfunction involving risperidone, olanzapine, and quetiapine and 
comparing them. Although a cross-sectional design is not always the best design for such studies, the problem of 
attrition seen in the prospective studies is not an issue here. Only the clinically stable patients were incorporated with a 
careful assessment on BPRS, as the patients' account is less reliable during the symptomatic phase. However, full 
remission is rarely achieved in schizophrenia, especially with respect to negative and cognitive symptoms. The current 
study is, to some extent, similar in methodology to that of Smith and colleagues. [6] However, the latter has not used 
BPRS. They have used the Calgary Depression Inventory to rule out depression among patients with schizophrenia, 
and the UKU side effect rating scale to assess the autonomic side effects. Various questionnaires addressing sexual 
function have been used in different studies. [2],[21],[22],[23] The problem with most of them is that the same 
questionnaire is not replicated in several further studies to enhance its validity. Furthermore, the reliability and validity 
of data collected by means of questionnaires are jeopardized by intentional nonreporting or over-reporting, incomplete 
recall, misunderstanding of survey questions, and selective participation. Therefore, the questionnaire is not entirely 
responsible for the credibility of the data. The current study has used the original SFQ, designed by Smith and 
colleagues, without any modification. It was based on the evidences that men with schizophrenia were able to answer 
direct questions regarding concrete aspects of sexual functioning. A sexual partner was not necessary to answer the 
questions in SFQ. In our patient population, the frequency of sexual dysfunction was much higher than in the original 
study by Smith and colleagues. This could be attributed to differences in factors such as dose and duration of treatment 
of the sample population, differing psychosocial environments, inherent biological variation among races, apart from 
the patient-related errors in answering the questionnaire as mentioned above. This study did not incorporate the 
determination of biological markers like the serum prolactin level, unlike other studies. [17],[18],[24],[25] Such an 
estimation could have further strengthened it. 
 
The duration of antipsychotic exposure is an important factor in impaired sexual functioning. In case of risperidone, 
the literature says that it behaves as a typical antipsychotic in doses of more than 6 mg/day. However, it might have the 
same effects even in lower doses when given for several years. Thus both dose and duration may have equally 
important roles. Any difference in sexual dysfunction due to higher and lower doses of each drug has not been 
compared in this study, as this was not the focus of this study. However, such a comparison may yield useful 
implications. This is another limitation of the present study. In the study by Bobes and co-researchers, although 
quetiapine was found to have lesser sexual dysfunction compared to risperidone and haloperidol, it was used for a 
shorter duration (12 weeks) and the author cites this as a limitation of his study. [7] In the present study though the 
duration of treatment among the three drugs was evenly distributed, there was a significant difference in the dose of 
study drugs. The chlorpromazine equivalent dose of quetiapine was significantly greater than the other study drugs, as 
mentioned earlier. This might be a significant factor in this study, as higher sexual dysfunction was observed with 
quetiapine compared to the earlier studies. This also indicates that quetiapine may be needed in relatively higher doses 
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Thus the results of this study allow no concrete conclusion to be made as to which atypical antipsychotic is 
significantly safer than the other as far as the sexual side effects are concerned. However, in future, such a research 
with similar methodology should involve the comparison of drugs with the chlorpromazine equivalent doses evenly 
matched. An attempt should also be made to compare individual drugs at higher versus lower doses. A study of 
prolactin levels is also a useful complimentary procedure. Also higher the sample size, better the inference. With all 
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